KalVista Plans Quick FDA Filing After Phase III Success In On-Demand HAE Therapy

 
• By Joseph Haas
  
Rare Diseases
KalVista hopes it has the latest advance in rare disease HAE • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D